GlobeNewswire Inc.··NaSCYNEXIS Grants Inducement Awards to New VP Under Nasdaq Rule 5635
SCYNEXIS grants 125,000 stock options at $0.93/share and 20,000 RSUs to new VP under Nasdaq inducement rules.
SCYXrestricted stock unitsstock options
ADPKD
3 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··Xortx Therapeutics Inc.XORTX Therapeutics Completes 1-for-5 Share Consolidation Effective April 6
XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.
XRTXclinical trialskidney disease
Benzinga··Globe NewswireSCYNEXIS Expands Pipeline With $8M PXL-770 Acquisition, Eyes Rare Kidney Disease Market
SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.
GSKSCYXacquisitionclinical development